Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study

Jochen Walz, Shahrokh F. Shariat, Nazareno Suardi, Paul Perrotte, Yair Lotan, Ganesh S. Palapattu, Amit Gupta, Patrick J. Bastian, Craig G. Rogers, Amnon Vazina, Gilad E. Amiel, Arthur I. Sagalowsky, Mark P. Schoenberg, Seth P. Lerner, Pierre I. Karakiewicz

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

OBJECTIVE: To assess the effect of adjuvant chemotherapy (ACHT; methotrexate, vinblastine, adriamycin and cisplatin, MVAC, or gemcitabine/cisplatin, GC) on the rate of cancer-specific survival and overall survival, as the benefit of ACHT after radical cystectomy (RC) for bladder cancer is controversial. PATIENTS AND METHODS: Within a study group of 958 patients treated with RC between 1984 and 2003, we identified 274 (29.0%) with a high risk of progression due to pT3 or pT4 and/or pN1-3 stages. Of these, 129 (46.6%) received ACHT (MVAC in 103, GC in 26). These patients were then matched with the remaining patients who were unexposed to ACHT. Exact matches were made for pT stage, tumour grade, pN stage and lymphovascular invasion. Age (±5 years) and year of surgery (±5 years) were calliper-matched. Matching resulted in 62 patients treated with RC/ACHT and 65 treated with RC alone. Kaplan-Meier, life-table and Cox regression analyses were used to assess cancer-specific and overall survival. RESULTS: There was no statistically significant difference in cancer-specific survival probabilities at 5 years after RC between the two groups (relative risk 1.2; P = 0.5). There was also no difference in overall survival at 5 years (1.1; P = 0.7). In multivariable analyses the delivery of adjuvant chemotherapy was not an independent predictor for survival endpoints (P = 0.3 for cancer-specific and 0.3 for overall survival). CONCLUSIONS: This matched case-control analysis showed that either MVAC or GC chemotherapy had no effect on cancer-specific or overall survival after RC in high-risk patients. Further randomized long-term studies are necessary to confirm these results.

Original languageEnglish (US)
Pages (from-to)1356-1361
Number of pages6
JournalBJU International
Volume101
Issue number11
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Cystectomy
Adjuvant Chemotherapy
Urinary Bladder Neoplasms
Case-Control Studies
Survival
Neoplasms
gemcitabine
Cisplatin
Life Tables
Vinblastine
Methotrexate
Doxorubicin
Regression Analysis
Drug Therapy

Keywords

  • Adjuvant chemotherapy
  • Bladder cancer
  • Cancer specific survival
  • Case control study
  • Cystectomy

ASJC Scopus subject areas

  • Urology

Cite this

Walz, J., Shariat, S. F., Suardi, N., Perrotte, P., Lotan, Y., Palapattu, G. S., ... Karakiewicz, P. I. (2008). Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU International, 101(11), 1356-1361. https://doi.org/10.1111/j.1464-410X.2008.07524.x

Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. / Walz, Jochen; Shariat, Shahrokh F.; Suardi, Nazareno; Perrotte, Paul; Lotan, Yair; Palapattu, Ganesh S.; Gupta, Amit; Bastian, Patrick J.; Rogers, Craig G.; Vazina, Amnon; Amiel, Gilad E.; Sagalowsky, Arthur I.; Schoenberg, Mark P.; Lerner, Seth P.; Karakiewicz, Pierre I.

In: BJU International, Vol. 101, No. 11, 06.2008, p. 1356-1361.

Research output: Contribution to journalArticle

Walz, J, Shariat, SF, Suardi, N, Perrotte, P, Lotan, Y, Palapattu, GS, Gupta, A, Bastian, PJ, Rogers, CG, Vazina, A, Amiel, GE, Sagalowsky, AI, Schoenberg, MP, Lerner, SP & Karakiewicz, PI 2008, 'Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study', BJU International, vol. 101, no. 11, pp. 1356-1361. https://doi.org/10.1111/j.1464-410X.2008.07524.x
Walz, Jochen ; Shariat, Shahrokh F. ; Suardi, Nazareno ; Perrotte, Paul ; Lotan, Yair ; Palapattu, Ganesh S. ; Gupta, Amit ; Bastian, Patrick J. ; Rogers, Craig G. ; Vazina, Amnon ; Amiel, Gilad E. ; Sagalowsky, Arthur I. ; Schoenberg, Mark P. ; Lerner, Seth P. ; Karakiewicz, Pierre I. / Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. In: BJU International. 2008 ; Vol. 101, No. 11. pp. 1356-1361.
@article{9811c646d1a841249ed1f11e63596085,
title = "Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study",
abstract = "OBJECTIVE: To assess the effect of adjuvant chemotherapy (ACHT; methotrexate, vinblastine, adriamycin and cisplatin, MVAC, or gemcitabine/cisplatin, GC) on the rate of cancer-specific survival and overall survival, as the benefit of ACHT after radical cystectomy (RC) for bladder cancer is controversial. PATIENTS AND METHODS: Within a study group of 958 patients treated with RC between 1984 and 2003, we identified 274 (29.0{\%}) with a high risk of progression due to pT3 or pT4 and/or pN1-3 stages. Of these, 129 (46.6{\%}) received ACHT (MVAC in 103, GC in 26). These patients were then matched with the remaining patients who were unexposed to ACHT. Exact matches were made for pT stage, tumour grade, pN stage and lymphovascular invasion. Age (±5 years) and year of surgery (±5 years) were calliper-matched. Matching resulted in 62 patients treated with RC/ACHT and 65 treated with RC alone. Kaplan-Meier, life-table and Cox regression analyses were used to assess cancer-specific and overall survival. RESULTS: There was no statistically significant difference in cancer-specific survival probabilities at 5 years after RC between the two groups (relative risk 1.2; P = 0.5). There was also no difference in overall survival at 5 years (1.1; P = 0.7). In multivariable analyses the delivery of adjuvant chemotherapy was not an independent predictor for survival endpoints (P = 0.3 for cancer-specific and 0.3 for overall survival). CONCLUSIONS: This matched case-control analysis showed that either MVAC or GC chemotherapy had no effect on cancer-specific or overall survival after RC in high-risk patients. Further randomized long-term studies are necessary to confirm these results.",
keywords = "Adjuvant chemotherapy, Bladder cancer, Cancer specific survival, Case control study, Cystectomy",
author = "Jochen Walz and Shariat, {Shahrokh F.} and Nazareno Suardi and Paul Perrotte and Yair Lotan and Palapattu, {Ganesh S.} and Amit Gupta and Bastian, {Patrick J.} and Rogers, {Craig G.} and Amnon Vazina and Amiel, {Gilad E.} and Sagalowsky, {Arthur I.} and Schoenberg, {Mark P.} and Lerner, {Seth P.} and Karakiewicz, {Pierre I.}",
year = "2008",
month = "6",
doi = "10.1111/j.1464-410X.2008.07524.x",
language = "English (US)",
volume = "101",
pages = "1356--1361",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study

AU - Walz, Jochen

AU - Shariat, Shahrokh F.

AU - Suardi, Nazareno

AU - Perrotte, Paul

AU - Lotan, Yair

AU - Palapattu, Ganesh S.

AU - Gupta, Amit

AU - Bastian, Patrick J.

AU - Rogers, Craig G.

AU - Vazina, Amnon

AU - Amiel, Gilad E.

AU - Sagalowsky, Arthur I.

AU - Schoenberg, Mark P.

AU - Lerner, Seth P.

AU - Karakiewicz, Pierre I.

PY - 2008/6

Y1 - 2008/6

N2 - OBJECTIVE: To assess the effect of adjuvant chemotherapy (ACHT; methotrexate, vinblastine, adriamycin and cisplatin, MVAC, or gemcitabine/cisplatin, GC) on the rate of cancer-specific survival and overall survival, as the benefit of ACHT after radical cystectomy (RC) for bladder cancer is controversial. PATIENTS AND METHODS: Within a study group of 958 patients treated with RC between 1984 and 2003, we identified 274 (29.0%) with a high risk of progression due to pT3 or pT4 and/or pN1-3 stages. Of these, 129 (46.6%) received ACHT (MVAC in 103, GC in 26). These patients were then matched with the remaining patients who were unexposed to ACHT. Exact matches were made for pT stage, tumour grade, pN stage and lymphovascular invasion. Age (±5 years) and year of surgery (±5 years) were calliper-matched. Matching resulted in 62 patients treated with RC/ACHT and 65 treated with RC alone. Kaplan-Meier, life-table and Cox regression analyses were used to assess cancer-specific and overall survival. RESULTS: There was no statistically significant difference in cancer-specific survival probabilities at 5 years after RC between the two groups (relative risk 1.2; P = 0.5). There was also no difference in overall survival at 5 years (1.1; P = 0.7). In multivariable analyses the delivery of adjuvant chemotherapy was not an independent predictor for survival endpoints (P = 0.3 for cancer-specific and 0.3 for overall survival). CONCLUSIONS: This matched case-control analysis showed that either MVAC or GC chemotherapy had no effect on cancer-specific or overall survival after RC in high-risk patients. Further randomized long-term studies are necessary to confirm these results.

AB - OBJECTIVE: To assess the effect of adjuvant chemotherapy (ACHT; methotrexate, vinblastine, adriamycin and cisplatin, MVAC, or gemcitabine/cisplatin, GC) on the rate of cancer-specific survival and overall survival, as the benefit of ACHT after radical cystectomy (RC) for bladder cancer is controversial. PATIENTS AND METHODS: Within a study group of 958 patients treated with RC between 1984 and 2003, we identified 274 (29.0%) with a high risk of progression due to pT3 or pT4 and/or pN1-3 stages. Of these, 129 (46.6%) received ACHT (MVAC in 103, GC in 26). These patients were then matched with the remaining patients who were unexposed to ACHT. Exact matches were made for pT stage, tumour grade, pN stage and lymphovascular invasion. Age (±5 years) and year of surgery (±5 years) were calliper-matched. Matching resulted in 62 patients treated with RC/ACHT and 65 treated with RC alone. Kaplan-Meier, life-table and Cox regression analyses were used to assess cancer-specific and overall survival. RESULTS: There was no statistically significant difference in cancer-specific survival probabilities at 5 years after RC between the two groups (relative risk 1.2; P = 0.5). There was also no difference in overall survival at 5 years (1.1; P = 0.7). In multivariable analyses the delivery of adjuvant chemotherapy was not an independent predictor for survival endpoints (P = 0.3 for cancer-specific and 0.3 for overall survival). CONCLUSIONS: This matched case-control analysis showed that either MVAC or GC chemotherapy had no effect on cancer-specific or overall survival after RC in high-risk patients. Further randomized long-term studies are necessary to confirm these results.

KW - Adjuvant chemotherapy

KW - Bladder cancer

KW - Cancer specific survival

KW - Case control study

KW - Cystectomy

UR - http://www.scopus.com/inward/record.url?scp=43049117575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049117575&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2008.07524.x

DO - 10.1111/j.1464-410X.2008.07524.x

M3 - Article

VL - 101

SP - 1356

EP - 1361

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 11

ER -